Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
B-cell lymphoma
Pharma
FDA OKs BMS' Breyanzi as first CAR-T for marginal zone lymphoma
With FDA approval to treat marginal zone lymphoma, BMS’ Breyanzi has become the first CAR-T therapy for the patient population.
Kevin Dunleavy
Dec 5, 2025 11:00am
Autolus enters CAR-T race with FDA approval for Aucatzyl
Nov 11, 2024 11:30am
Roche guilty of serious marketing breach for Polivy website
Jul 14, 2023 9:40am
Gilead's Yescarta scoops up overall survival win
Mar 21, 2023 11:38am
NICE signs off on BeiGene's Brukinsa for blood cancer disorder
Sep 20, 2022 10:10am
BMS' CAR-T pressures Gilead in 2L lymphoma with broader nod
Jun 24, 2022 11:11pm
